Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

Ronan Mahon (), Andrea Lang (), Pamela Vo (), Jasper Huels (), Philip Cooney (), Andriy Danyliv (), Umakanth Vudumula (), Sreelatha Vadapalle (), Farooq Maniyar () and Peter J. Goadsby ()
Additional contact information
Ronan Mahon: Novartis Ireland Limited
Andrea Lang: Novartis Sverige AB
Pamela Vo: Novartis Pharma AG
Jasper Huels: Novartis Pharma AG
Philip Cooney: Novartis Ireland Limited
Andriy Danyliv: Novartis Ireland Limited
Umakanth Vudumula: Novartis Healthcare Private Limited
Sreelatha Vadapalle: Novartis Healthcare Private Limited
Farooq Maniyar: Basildon and Thurrock University Hospitals and Queen Mary University
Peter J. Goadsby: King’s College London

PharmacoEconomics, 2021, vol. 39, issue 3, No 7, 357-372

Abstract: Abstract Background Migraine is a common neurological disease that disproportionately affects females and has a peak incidence during productive years, resulting in significant burden. Objective The aim of the study was to determine the cost effectiveness of erenumab for the preventive treatment of migraine. Methods A hybrid decision-tree plus Markov model was developed to evaluate the cost effectiveness of erenumab as a migraine treatment compared with best supportive care only for patients experiencing at least 4 monthly migraine days for whom at least two prior preventive treatments had failed. Clinical efficacy data were based on results from four randomized controlled trials of erenumab against placebo. The primary outcomes were costs, migraine days, and quality-adjusted life-years (QALYs). An incremental cost-effectiveness ratio (ICER) was estimated as the cost per QALY gained. The cost per migraine day avoided was also estimated, as were disaggregated direct and indirect costs. The analysis was conducted from Swedish societal and healthcare system perspectives based on total migraine, chronic migraine and episodic migraine populations, using a discount rate of 3% applied to both costs and health benefits and using year 2019 values. Results In the base-case deterministic analyses, erenumab treatment resulted in ICERs of Swedish krona (SEK) 34,696 (€3310) and SEK301,565 (€28,769) per QALY gained in the total migraine and episodic migraine populations, respectively. Erenumab was dominant in the chronic migraine population. In the total migraine population, the use of erenumab resulted in a net benefit to society of SEK81,739 (€7773) per patient, assuming a willingness-to-pay threshold of SEK300,000 (€28,528) per QALY. Conclusions Our analysis suggests that erenumab is a cost-effective treatment for migraine with a willingness-to-pay threshold of SEK300,000 per QALY.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-020-00996-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:3:d:10.1007_s40273-020-00996-2

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-020-00996-2

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().